Piperaquine Tetraphosphate PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
A bisquinoline antimalarial that interferes with haem detoxification in Plasmodium parasites, leading to accumulation of toxic haem species and parasite death. It is used clinically in combination with dihydroartemisinin; phosphate is a salt component, not a distinct active target.
Indications / reported uses
Treatment of uncomplicated Plasmodium falciparum malaria as part of the fixed-dose dihydroartemisinin–piperaquine combination, in accordance with current national malaria guidelines and resistance patterns
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Piperaquine Tetraphosphate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Piperaquine Tetraphosphate Permitted Daily Exposure (PDE) report (the Piperaquine Tetraphosphate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Piperaquine Tetraphosphate Occupational Exposure Limit (OEL) report (the Piperaquine Tetraphosphate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.